Výsledky vyhledávání - "Douglas Scriba"

Incidence of EGFR, kras, BRAF, ALK, and p53 alterations in a cohort of 218 consecutively tested patients from a certified lung cancer center: Correlation with clinical characteristics and treatment outcome

Autor: Markus Falk, Douglas Scriba, Markus Tiemann, Kay Willborn, Cora Hallas, Volker Halbfass, Anne Christina Lueers, Frank Griesinger, Regina Prenzel

Publikováno v: Journal of Clinical Oncology. 32:e19064-e19064

e19064 Background: The aim of the study was to systematically analyze EGFR, KRAS, BRAF, ALK and p53 within the same cohort of patients, to correlate alterations with clinical characteristics and to...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9ea08a3b0729bd2804989b29d198a6a
https://doi.org/10.1200/jco.2014.32.15_suppl.e19064

Zobrazit plný text záznamu

Second-line chemotherapy exposure in a German cancer society certified lung cancer center: Single-center experience of 4 years and relevance for maintenance therapy

Autor: Kay Willborn, Frank Griesinger, Regina Prenzel, Douglas Scriba, Volker Halbfass, Anne Christina Lueers

Publikováno v: Journal of Clinical Oncology. 32:e19097-e19097

e19097 Background: One of the strongest rationale for maintenance therapy in NSCLC is the fact that exposure to 2nd line therapy is only 40-60% in clinical trials in specialized treatment centers. Even with follow-up intervals of 6 weeks, the 2nd lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3f8dd09e668ecccbbd3fcfef7c856c9
https://doi.org/10.1200/jco.2014.32.15_suppl.e19097

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání